CoChat

Adipose Tissue Macrophages Function As Antigen-Presenting Cells and Regulate Adipose Tissue CD4+ T Cells in Mice

Open access

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

The proinflammatory activation of leukocytes in adipose tissue contributes to metabolic disease. How crosstalk between immune cells initiates and sustains adipose tissue inflammation remains an unresolved question. We have examined the hypothesis that adipose tissue macrophages (ATMs) interact with and regulate the function of T cells. Dietary obesity was shown to activate the proliferation of effector memory CD4+ T cells in adipose tissue. Our studies further demonstrate that ATMs are functional antigen-presenting cells that promote the proliferation of interferon-γ–producing CD4+ T cells in adipose tissue. ATMs from lean and obese visceral fat process and present major histocompatibility complex (MHC) class II–restricted antigens. ATMs were sufficient to promote proliferation and interferon-γ production from antigen-specific CD4+ T cells in vitro and in vivo. Diet-induced obesity increased the expression of MHC II and T-cell costimulatory molecules on ATMs in visceral fat, which correlated with an induction of T-cell proliferation in that depot. Collectively, these data indicate that ATMs provide a functional link between the innate and adaptive immune systems within visceral fat in mice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db12-1404

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. Adipose tissue CD4+ T-cell proliferation is induced in visceral fat in response to dietary obesity. Male C57BL/6 mice were fed ND or HFD (60% fat) for 14 to 17 weeks. BrdU was added to the drinking water for 5 consecutive days before splenocytes and adipose tissue stromal cells were isolated and analyzed by flow cytometry. A: Representative histogram shows BrdU incorporation in CD3+ CD4+ ATTs in eWAT from ND (dashedline) and HFD (solidline) mice. Isotype (ISO; shaded) is shown. B: Quantification of BrdU+ CD4+ T cells (expressed as percentage of viable CD3+ CD4+ lymphocytes) in eWAT, iWAT, and spleen from ND and HFD mice. Data are means ± SEM (ND eWAT: n = 5–6; HFD eWAT: n = 10; iWAT and spleen: n = 4 mice per group). C: Quantification of BrdU+ effector-memory (E/M; CD44High CD62L−), central-memory (C/M; CD44High CD62L+), and naïve (CD44Low CD62L+) CD4+ ATT subsets in eWAT from ND and HFD mice. Data are means ± SEM (ND: n = 3–4; HFD: n = 5–6 mice per group). D: Representative scatterplots (Foxp3 vs. BrdU) of viable CD3+ CD4+ ATTs demonstrating proliferation of conventional (Tconv, Foxp3−) and regulatory (Treg, Foxp3+) CD4+ T cells in eWAT from ND and HFD mice. E: Quantification of proliferating Tconvs and Tregs in eWAT from ND and HFD mice. Data are means ± SEM (ND: n = 3; HFD: n = 5 mice per group). BrdU+ (green) and CD4+ (red) lymphocytes were identified by confocal microscopy (original magnification ×60) in CLS (F) and FALC (G) within eWAT fat from HFD mice. Bar = 50 μm for F and G. H: Identification of Foxp3+ lymphocytes (red) in proximity to GFP+ ATMs (green) in FALCs in eWAT from a ND Cx3cr1GFP/+ reporter mouse. Scale bar = 100 μm. *P < 0.05, **P < 0.01 for ND vs. HFD.
FIG. 1. Adipose tissue CD4+ T-cell proliferation is induced in visceral fat in response to dietary obesity. Male C57BL/6 mice were fed ND or HFD (60% fat) for 14 to 17 weeks. BrdU was added to the drinking water for 5 consecutive days before splenocytes and adipose tissue stromal cells were isolated and analyzed by flow cytometry. A: Representative histogram shows BrdU incorporation in CD3+ CD4+ ATTs in eWAT from ND (dashedline) and HFD (solidline) mice. Isotype (ISO; shaded) is shown. B: Quantification of BrdU+ CD4+ T cells (expressed as percentage of viable CD3+ CD4+ lymphocytes) in eWAT, iWAT, and spleen from ND and HFD mice. Data are means ± SEM (ND eWAT: n = 5–6; HFD eWAT: n = 10; iWAT and spleen: n = 4 mice per group). C: Quantification of BrdU+ effector-memory (E/M; CD44High CD62L−), central-memory (C/M; CD44High CD62L+), and naïve (CD44Low CD62L+) CD4+ ATT subsets in eWAT from ND and HFD mice. Data are means ± SEM (ND: n = 3–4; HFD: n = 5–6 mice per group). D: Representative scatterplots (Foxp3 vs. BrdU) of viable CD3+ CD4+ ATTs demonstrating proliferation of conventional (Tconv, Foxp3−) and regulatory (Treg, Foxp3+) CD4+ T cells in eWAT from ND and HFD mice. E: Quantification of proliferating Tconvs and Tregs in eWAT from ND and HFD mice. Data are means ± SEM (ND: n = 3; HFD: n = 5 mice per group). BrdU+ (green) and CD4+ (red) lymphocytes were identified by confocal microscopy (original magnification ×60) in CLS (F) and FALC (G) within eWAT fat from HFD mice. Bar = 50 μm for F and G. H: Identification of Foxp3+ lymphocytes (red) in proximity to GFP+ ATMs (green) in FALCs in eWAT from a ND Cx3cr1GFP/+ reporter mouse. Scale bar = 100 μm. *P < 0.05, **P < 0.01 for ND vs. HFD.CC BY-NC-ND · PubMed Central
FIG. 2. ATMs are the predominant MHC II+ cells in visceral fat. Male C57BL/6 mice were fed ND or HFD for 20 weeks to induce obesity. A: MHC I-A/I-E+ (green) ATMs were identified by epifluorescence microscopy dispersed between adipocytes. Bar = 100 μm. B: Identification of MGL1+ (green) and MHC I-A/I-E+ (red) ATMs in eWAT from ND mice. C and D: MHC I-A/I-E+ (green) ATMs in eWAT from HFD mice. Isolectin (red) stains blood vessels. Bar = 100 μm. E: Concentration of MHC I-A/I-E+ (red) ATMs in MGL1− (green) CLS in eWAT from HFD mice. F: MHC I-A/I-E (green) expression in a FALC in eWAT from HFD mice. Bar = 100 μm. G: H2-Ab1 gene expression in eWAT, iWAT, and spleen from ND and HFD mice. Data are means ± SEM (ND eWAT: n = 5; HFD eWAT: n = 6; iWAT: n = 5; spleen: n = 3 mice per group). H: Ciita gene expression in eWAT and spleen from ND and HFD mice (ND eWAT: n = 5; HFD eWAT: n = 6; spleen: n = 3 mice per group). I: Expression of Ciita transcripts from type I (DC), type III (B cell), and type IV (IFN-γ) promoters in eWAT from ND and HFD mice (ND: n = 5; HFD: n = 6). J: H2-Ab1 expression in FACS-sorted ATMs (F4/80+ CD11b+) and non-ATMs (F4/80− CD11b−) from ND and HFD eWAT. Data are means ± SEM (n = 4 per group). K: Surface expression of MHC I-A/I-E on ATMs (F4/80+ CD11b+ SVCs; thick line) and non-ATMs (F4/80− CD11b− SVCs; dashed line) isolated from ND and obese HFD mice. Isotype (ISO; shaded) is shown. L: Quantification of ATMs expressing MHC I-A/I-E and non-ATMs in eWAT from ND and HFD mice. Data are means ± SEM (n = 4 per group). M: MHC I-A/I-E expression (MFI, mean fluorescent intensity) on CD11c− and CD11c+ ATMs from eWAT of HFD mice as determined by flow cytometry. Data are means ± SEM (n = 4 mice). *P < 0.05, **P < 0.01, ***P < 0.001.
FIG. 2. ATMs are the predominant MHC II+ cells in visceral fat. Male C57BL/6 mice were fed ND or HFD for 20 weeks to induce obesity. A: MHC I-A/I-E+ (green) ATMs were identified by epifluorescence microscopy dispersed between adipocytes. Bar = 100 μm. B: Identification of MGL1+ (green) and MHC I-A/I-E+ (red) ATMs in eWAT from ND mice. C and D: MHC I-A/I-E+ (green) ATMs in eWAT from HFD mice. Isolectin (red) stains blood vessels. Bar = 100 μm. E: Concentration of MHC I-A/I-E+ (red) ATMs in MGL1− (green) CLS in eWAT from HFD mice. F: MHC I-A/I-E (green) expression in a FALC in eWAT from HFD mice. Bar = 100 μm. G: H2-Ab1 gene expression in eWAT, iWAT, and spleen from ND and HFD mice. Data are means ± SEM (ND eWAT: n = 5; HFD eWAT: n = 6; iWAT: n = 5; spleen: n = 3 mice per group). H: Ciita gene expression in eWAT and spleen from ND and HFD mice (ND eWAT: n = 5; HFD eWAT: n = 6; spleen: n = 3 mice per group). I: Expression of Ciita transcripts from type I (DC), type III (B cell), and type IV (IFN-γ) promoters in eWAT from ND and HFD mice (ND: n = 5; HFD: n = 6). J: H2-Ab1 expression in FACS-sorted ATMs (F4/80+ CD11b+) and non-ATMs (F4/80− CD11b−) from ND and HFD eWAT. Data are means ± SEM (n = 4 per group). K: Surface expression of MHC I-A/I-E on ATMs (F4/80+ CD11b+ SVCs; thick line) and non-ATMs (F4/80− CD11b− SVCs; dashed line) isolated from ND and obese HFD mice. Isotype (ISO; shaded) is shown. L: Quantification of ATMs expressing MHC I-A/I-E and non-ATMs in eWAT from ND and HFD mice. Data are means ± SEM (n = 4 per group). M: MHC I-A/I-E expression (MFI, mean fluorescent intensity) on CD11c− and CD11c+ ATMs from eWAT of HFD mice as determined by flow cytometry. Data are means ± SEM (n = 4 mice). *P < 0.05, **P < 0.01, ***P < 0.001.CC BY-NC-ND · PubMed Central
FIG. 3. Expression of costimulatory molecules on ATMs is regulated by dietary obesity, inflammatory stimuli, and adipocyte signals. Male C57BL/6 mice were fed ND or HFD for 20 weeks. Cd40, Cd80, and Cd86 expression in eWAT (A), spleen (B), and iWAT (C) from ND and HFD mice. Data are means ± SEM (eWAT: n = 5–6; iWAT: n = 5; spleen: n = 3 mice per group). D: Cd40 expression in FACS-sorted ATMs (F4/80+ CD11b+) and non-ATMs (F4/80− CD11b−) from ND and HFD eWAT. Data are means ± SEM (n = 4 per group). Cd40 (E) and Cd80 (F) expression in cultured SVCs from HFD mice stimulated with IL-4 (20 ng/mL), LPS (100 ng/mL), IFN-γ (5 ng/mL), or LPS (100 ng/mL) plus IFN-γ (5 ng/mL) for 24 h. Data are means ± SEM (n = 3 wells) and are representative of two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
FIG. 3. Expression of costimulatory molecules on ATMs is regulated by dietary obesity, inflammatory stimuli, and adipocyte signals. Male C57BL/6 mice were fed ND or HFD for 20 weeks. Cd40, Cd80, and Cd86 expression in eWAT (A), spleen (B), and iWAT (C) from ND and HFD mice. Data are means ± SEM (eWAT: n = 5–6; iWAT: n = 5; spleen: n = 3 mice per group). D: Cd40 expression in FACS-sorted ATMs (F4/80+ CD11b+) and non-ATMs (F4/80− CD11b−) from ND and HFD eWAT. Data are means ± SEM (n = 4 per group). Cd40 (E) and Cd80 (F) expression in cultured SVCs from HFD mice stimulated with IL-4 (20 ng/mL), LPS (100 ng/mL), IFN-γ (5 ng/mL), or LPS (100 ng/mL) plus IFN-γ (5 ng/mL) for 24 h. Data are means ± SEM (n = 3 wells) and are representative of two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.CC BY-NC-ND · PubMed Central
FIG. 4. ATMs in visceral fat are efficient phagocytes capable of processing model antigens. A: Identification of fluorescent OVA (green) in F4/80+ (red) ATMs in eWAT by confocal microscopy 1 h after intraperitoneal injection of FITC-conjugated OVA. Bar = 50 μm; original magnification ×40. B: Immunofluorescence image of fluorescent OVA (red) in a FALC in eWAT from a lean mouse. Scale bar = 100 μm. SVCs were isolated from HFD-fed (20 weeks) male mice and cultured for 18 h. Adherent cells were incubated with FITC-conjugated OVA or FITC-labeled ZymosanA particles for 1 h before immunostaining with indicated antibodies and imaged by confocal microscopy (original magnification ×63). Ex vivo uptake of FITC-OVA (green) was observed in adherent F4/80+ (red) (C), MHC I-A/I-E+ (red) (D), and CD11c+ (red) cells (E). F: Phagocytosis of ZymosanA particles (green) by cultured F4/80+ ATMs (red). Scale bar = 50 μm for C–F. Lean mice were injected intraperitoneally with DQ-OVA (100 μg/mouse). SVCs from eWAT and peritoneal macrophages were isolated 1 h later and stained for flow cytometry analysis. Representative scatterplots show DQ-OVAHigh cells in ATMs expressing MHC I-A/I-E (F4/80+ CD11b+) (G) and non-ATMs (F4/80− CD11b−) (H) from eWAT. I: DQ-OVA signals were detected in peritoneal macrophages (PMϕ; F4/80+ CD11bHigh) from the same mouse; the percentage of gated cells is indicated in each quadrant.
FIG. 4. ATMs in visceral fat are efficient phagocytes capable of processing model antigens. A: Identification of fluorescent OVA (green) in F4/80+ (red) ATMs in eWAT by confocal microscopy 1 h after intraperitoneal injection of FITC-conjugated OVA. Bar = 50 μm; original magnification ×40. B: Immunofluorescence image of fluorescent OVA (red) in a FALC in eWAT from a lean mouse. Scale bar = 100 μm. SVCs were isolated from HFD-fed (20 weeks) male mice and cultured for 18 h. Adherent cells were incubated with FITC-conjugated OVA or FITC-labeled ZymosanA particles for 1 h before immunostaining with indicated antibodies and imaged by confocal microscopy (original magnification ×63). Ex vivo uptake of FITC-OVA (green) was observed in adherent F4/80+ (red) (C), MHC I-A/I-E+ (red) (D), and CD11c+ (red) cells (E). F: Phagocytosis of ZymosanA particles (green) by cultured F4/80+ ATMs (red). Scale bar = 50 μm for C–F. Lean mice were injected intraperitoneally with DQ-OVA (100 μg/mouse). SVCs from eWAT and peritoneal macrophages were isolated 1 h later and stained for flow cytometry analysis. Representative scatterplots show DQ-OVAHigh cells in ATMs expressing MHC I-A/I-E (F4/80+ CD11b+) (G) and non-ATMs (F4/80− CD11b−) (H) from eWAT. I: DQ-OVA signals were detected in peritoneal macrophages (PMϕ; F4/80+ CD11bHigh) from the same mouse; the percentage of gated cells is indicated in each quadrant.CC BY-NC-ND · PubMed Central
FIG. 5. ATMs activate MHC II–restricted antigen-dependent CD4+ T-cell proliferation and Th1 polarization in vitro. SVCs were prepared from eWAT of lean (ND) and obese (HFD) mice and cultured overnight. Adherent cells were pulsed with the indicated amount of OVA peptide (323–339) or full OVA protein for 2 h before CFSE-labeled CD4+ cells from OT-II mice were added. After 5 days, CFSE dilution was determined by flow cytometry to quantify proliferating CD4+ cells in cocultures. Cytokines were measured by ELISA. A: Representative histograms demonstrate antigen-induced proliferation of CFSE-labeled OT-II CD4+ T cells in cocultures containing OVA peptide-pulsed SVCs from eWAT of lean (ND) and obese (HFD) mice. B: Quantitation of OT-II T-cell proliferation in cultures containing ND and HFD SVCs and increasing concentrations of OVA peptide. C: CD4+ T-cell proliferation in cultures containing OVA peptide-pulsed HFD SVCs in the presence (αMHC II) or absence (IgG) of MHC II–neutralizing antibodies. D: OT-II CD4+ T-cell proliferation induced by FACS-purified ATMs (F4/80+ CD11b+) and non-ATMs (F4/80− CD11b−) from HFD mice pulsed with OVA peptide. E: OT-II T-cell proliferation induced by ATMs from HFD mice pulsed with whole OVA protein. F: IFN-γ, IL-4, and IL-10 production in cocultures containing ND and HFD SVCs loaded with the indicated amounts of OVA peptide. G: IL-17 and IL-2 production in cocultures containing HFD SVCs pulsed with OVA peptide. nd = not detected. H: IFN-γ and IL-2 production in cocultures containing FACS-purified ATMs and non-ATMs from HFD mice loaded with OVA peptide before addition of CFSE-labeled OT-II CD4+ cells. B–H: Data are means ± SEM (n = 3–4 wells) and are representative of two to three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control.
FIG. 5. ATMs activate MHC II–restricted antigen-dependent CD4+ T-cell proliferation and Th1 polarization in vitro. SVCs were prepared from eWAT of lean (ND) and obese (HFD) mice and cultured overnight. Adherent cells were pulsed with the indicated amount of OVA peptide (323–339) or full OVA protein for 2 h before CFSE-labeled CD4+ cells from OT-II mice were added. After 5 days, CFSE dilution was determined by flow cytometry to quantify proliferating CD4+ cells in cocultures. Cytokines were measured by ELISA. A: Representative histograms demonstrate antigen-induced proliferation of CFSE-labeled OT-II CD4+ T cells in cocultures containing OVA peptide-pulsed SVCs from eWAT of lean (ND) and obese (HFD) mice. B: Quantitation of OT-II T-cell proliferation in cultures containing ND and HFD SVCs and increasing concentrations of OVA peptide. C: CD4+ T-cell proliferation in cultures containing OVA peptide-pulsed HFD SVCs in the presence (αMHC II) or absence (IgG) of MHC II–neutralizing antibodies. D: OT-II CD4+ T-cell proliferation induced by FACS-purified ATMs (F4/80+ CD11b+) and non-ATMs (F4/80− CD11b−) from HFD mice pulsed with OVA peptide. E: OT-II T-cell proliferation induced by ATMs from HFD mice pulsed with whole OVA protein. F: IFN-γ, IL-4, and IL-10 production in cocultures containing ND and HFD SVCs loaded with the indicated amounts of OVA peptide. G: IL-17 and IL-2 production in cocultures containing HFD SVCs pulsed with OVA peptide. nd = not detected. H: IFN-γ and IL-2 production in cocultures containing FACS-purified ATMs and non-ATMs from HFD mice loaded with OVA peptide before addition of CFSE-labeled OT-II CD4+ cells. B–H: Data are means ± SEM (n = 3–4 wells) and are representative of two to three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control.CC BY-NC-ND · PubMed Central
FIG. 6. Induction of antigen-dependent CD4+ T-cell proliferation in adipose tissue in vivo. A: Proliferation of adoptively transferred CFSE-labeled OT-II CD4+ cells in eWAT from lean mice 3 days after intraperitoneal injection of OVA or BSA. Quantitation of adoptively transferred (CD45.2+) (B) and total (C) CD4+ cells in eWAT, omental (oWAT), and mesenteric (mWAT) fat depots and spleen from lean mice 3 days after intraperitoneal injection of OVA or BSA. Data are means ± SEM (n = 4 per group). Purified CD4+ OT-II T cells were adoptively transferred into obese mice (12 weeks on HFD). OVA or BSA was injected intraperitoneally 24 h after adoptive transfer. Cells from eWAT, spleen, and blood were analyzed by flow cytometry 5 days after antigen exposure. D: ATM and ATT content in eWAT from HFD mice. E: CD3+ ATTs in eWAT from HFD mice expressed as a percentage of SVCs. F: Quantification of CD4+ and CD8+ T cells in eWAT and blood from HFD mice. G: Quantification of Ki-67+ CD4+ T cells in eWAT and spleen from HFD mice. H: Quantification of ATM subtypes in eWAT from HFD mice. DN, double negative; DP, double positive. I: Random-fed blood glucose and plasma insulin levels in HFD mice. D–I: Data are means ± SEM (n = 3 mice per group). *P < 0.05, **P < 0.01, ***P < 0.001 vs. control (BSA).
FIG. 6. Induction of antigen-dependent CD4+ T-cell proliferation in adipose tissue in vivo. A: Proliferation of adoptively transferred CFSE-labeled OT-II CD4+ cells in eWAT from lean mice 3 days after intraperitoneal injection of OVA or BSA. Quantitation of adoptively transferred (CD45.2+) (B) and total (C) CD4+ cells in eWAT, omental (oWAT), and mesenteric (mWAT) fat depots and spleen from lean mice 3 days after intraperitoneal injection of OVA or BSA. Data are means ± SEM (n = 4 per group). Purified CD4+ OT-II T cells were adoptively transferred into obese mice (12 weeks on HFD). OVA or BSA was injected intraperitoneally 24 h after adoptive transfer. Cells from eWAT, spleen, and blood were analyzed by flow cytometry 5 days after antigen exposure. D: ATM and ATT content in eWAT from HFD mice. E: CD3+ ATTs in eWAT from HFD mice expressed as a percentage of SVCs. F: Quantification of CD4+ and CD8+ T cells in eWAT and blood from HFD mice. G: Quantification of Ki-67+ CD4+ T cells in eWAT and spleen from HFD mice. H: Quantification of ATM subtypes in eWAT from HFD mice. DN, double negative; DP, double positive. I: Random-fed blood glucose and plasma insulin levels in HFD mice. D–I: Data are means ± SEM (n = 3 mice per group). *P < 0.05, **P < 0.01, ***P < 0.001 vs. control (BSA).CC BY-NC-ND · PubMed Central
FIG. 7. MHC II neutralization reduces CD4+ ATTs in obese mice but does not impact inflammation or glucose homeostasis. Mice were fed HFD for 14 weeks to induce obesity. Purified MHC I-A/I-E (αMHC II) or control (IgG; rat IgG2b) monoclonal antibodies were injected intraperitoneally every 48 h for 18 consecutive days. Quantification of total CD3+ ATTs (A) and total CD4+ and CD8+ ATTs (B) in eWAT of HFD mice after treatment. C: Treg content in eWAT from treated mice. D: Relative frequency of CD4+ T cells (as % total CD3+ T lymphocytes) in eWAT, spleen, and lymph nodes (LN). E: Tnfa, Il6, Il10, and Ifng expression in total eWAT from HFD mice after treatment. F: Fasting blood glucose levels (day 15) and random-fed plasma insulin levels (day 17) in HFD mice. G: Glucose tolerance test (GTT) performed in HFD mice 11 days after treatment. Data are means ± SEM (n = 3 mice per group). *P < 0.05 vs. control (IgG).
FIG. 7. MHC II neutralization reduces CD4+ ATTs in obese mice but does not impact inflammation or glucose homeostasis. Mice were fed HFD for 14 weeks to induce obesity. Purified MHC I-A/I-E (αMHC II) or control (IgG; rat IgG2b) monoclonal antibodies were injected intraperitoneally every 48 h for 18 consecutive days. Quantification of total CD3+ ATTs (A) and total CD4+ and CD8+ ATTs (B) in eWAT of HFD mice after treatment. C: Treg content in eWAT from treated mice. D: Relative frequency of CD4+ T cells (as % total CD3+ T lymphocytes) in eWAT, spleen, and lymph nodes (LN). E: Tnfa, Il6, Il10, and Ifng expression in total eWAT from HFD mice after treatment. F: Fasting blood glucose levels (day 15) and random-fed plasma insulin levels (day 17) in HFD mice. G: Glucose tolerance test (GTT) performed in HFD mice 11 days after treatment. Data are means ± SEM (n = 3 mice per group). *P < 0.05 vs. control (IgG).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 217

Metadata

Authors
Morris, D. L., Cho, K. W., DelProposto, J. L., Oatmen, K. E., Geletka, L. M., Martinez-Santibanez, G., Singer, K., & Lumeng, C. N.
Affiliations
  • Michigan Medicine (US)
  • University of Michigan (US)
  • Cellular and Molecular Biology Graduate Program, University of Michigan Medical School, Ann Arbor, Michigan
Corresponding author
Lumeng, Carey N.
Venue
Diabetes
Published
2013-07-17
Volume
62
Issue
8
Pages
2762-2772
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2130657795
Cited by
217
References
48
Citations by year
2026: 6 · 2025: 8 · 2024: 6 · 2023: 13 · 2022: 17 · 2021: 11 · 2020: 23 · 2019: 17 · 2018: 20 · 2017: 18 · 2016: 20 · 2015: 24 · 2014: 21 · 2013: 13
FWCI
18.98
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Institute of General Medical Sciences (T32GM007315, T32GM008322)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK-078851, DK-087999, P60DK020572, R21DK092873, F32DK091976, DK089503, R01DK090262, DK-091976, DK092873, DK090262, K08DK078851, R03DK087999, P30DK020572, P30DK089503)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (F32HD008513, T32-HD-008513, K12HD028820)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
Keywords
adipose tissue macrophages, antigen presentation, CD4+ T cells, diet-induced obesity, visceral fat, interferon-gamma, MHC class II, T cell costimulatory molecules, T cell proliferation, adipose tissue inflammation, innate-adaptive immune crosstalk, metabolic disorders
MeSH terms
Adipose Tissue, Animals, Antigen-Presenting Cells, Diet, Glucose Tolerance Test, Inflammation, Insulin, Insulin Resistance, Lymphocyte Activation, Macrophages, Obesity, Phagocytosis, CD4-Positive T-Lymphocytes, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.